Fate Therapeutics (FATE) Retained Earnings (2012 - 2026)
Fate Therapeutics (FATE) posted Retained Earnings of -$1.6 billion for Q1 2026, down 1349687.93% on a QoQ basis from $116000.0 in Q4 2025, and down 819745.03% year-over-year from N/an in Q1 2025.
Fate Therapeutics (FATE) Retained Earnings (2012 - 2026) Analysis & Trends
Fate Therapeutics' Retained Earnings history runs 15 years deep, the most recent figure standing at -$1.6 billion for Q1 2026.
- Quarterly Retained Earnings fell 819745.03% year-over-year to -$1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 billion (down 819745.03% YoY) and the FY2025 annual result came in at $116000.0, down 56.72% from the prior year.
- Retained Earnings was -$1.6 billion for Q1 2026 at Fate Therapeutics, down from $116000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $1.6 billion in Q4 2023 and bottomed at -$1.6 billion in Q1 2026.
- A 5-year average of -$412.3 million and a median of -$646000.0 in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings jumped 250.36% — and 2026, when it slumped 819745.03%.
- Fate Therapeutics' Retained Earnings stood at -$1.1 billion in 2022, then soared by 250.36% to $1.6 billion in 2023, then plunged by 99.98% to $268000.0 in 2024, then tumbled by 56.72% to $116000.0 in 2025, then sank by 1349687.93% to -$1.6 billion in 2026.
- Business Quant data shows FATE's Retained Earnings at -$1.6 billion in Q1 2026, $116000.0 in Q4 2025, and -$1.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -27.89 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -279.01 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 12.91 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -622,000.00 |
| 10 | Fate Therapeutics | 288.82 Mn | 288.82 Mn | - | -1.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.57 Bn |
| Dec 31, 2025 | 116,000.00 |
| Sep 30, 2025 | -1.50 Bn |
| Jun 30, 2025 | -1.47 Bn |
| Mar 31, 2025 | 191,000.00 |
| Dec 31, 2024 | 268,000.00 |
| Sep 30, 2024 | 835,000.00 |
| Jun 30, 2024 | -422,000.00 |
| Mar 31, 2024 | -194,000.00 |
| Dec 31, 2023 | 1.58 Bn |
| Sep 30, 2023 | -1.17 Bn |
| Jun 30, 2023 | -587,000.00 |
| Mar 31, 2023 | -646,000.00 |
| Dec 31, 2022 | -1.05 Bn |
| Sep 30, 2022 | -994.44 Mn |
| Jun 30, 2022 | -3.38 Mn |
| Mar 31, 2022 | -834.77 Mn |
| Dec 31, 2021 | 1.45 Bn |
| Sep 30, 2021 | 1.43 Bn |
| Jun 30, 2021 | 1.41 Bn |